You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa Menstrual Migraine study—despite tough Covid-19 restrictions, and continued preparations for our Phase IIa study in Tourette syndrome. We remain confident of completing both studies on schedule, so realizing our vision…
Full PDFAsarina Pharma AB (publ) (ASAP: FN Stockholm) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited as scheduled at seven test centers across Sweden and Finland despite Covid-19 restrictions. Sepranolone, the endogenous compound being tested for MM, is the first therapy to focus exclusively on menstrual…
Full PDFAsarina Pharma CEO Peter Nordkild: “The second Quarter 2020 has given us continued proof of the urgent need for new, safe and effective treatments for the devastating conditions that our flagship compound, Sepranolone, targets. Despite disappointing results in our Phase IIb PMDD study at the beginning of the Quarter, which we covered extensively in our…
Full PDFAsarina Pharma CEO Peter Nordkild: “In April 2020 we released inconclusive topline results from our phase IIb study in PMDD. Although disappointing, these results do not invalidate our 40 years’ research into allopregnanolone and Sepranolone. Allopregnanolone remains implicated in a wide range of stress- and compulsion-related disorders, from Tourette to menstrual migraine to OCD, PTSD,…
Full PDFToday, on 5 May 2020, Asarina Pharma AB (publ) held its Annual General Meeting (“AGM”) in Stockholm. The AGM elected the Chairman of the Board of Directors Paul de Potocki, as chairman of the meeting and lawyer Nina Johnsson with Fredersen Advokatbyrå was keeper of the minutes. All the resolutions adopted by the AGM were…
Full PDF